L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB

Michio Fukuda¹, Yoshiaki Ogiyama¹, Ryo Sato¹, Toshiyuki Miura¹, Hidekatsu Fukuta¹, Masashi Mizuno¹, Ken Kiyono², Yoshiharu Yamamoto³, Junichiro Hayano⁴ and Nobuyuki Ohte¹

Abstract
Introduction: Increased sympathetic nerve activity has been suggested in patients with chronic kidney disease (CKD). Pathologic sympathetic activity can alter heart rate variability (HRV), and the altered HRV has prognostic importance, so that reducing sympathetic activity may be an important strategy. Novel nonlinear HRVs, including deceleration capacity (DC), have greater predictive power for mortality. We have recently proposed an increase in a non-Gaussianity index of HRV, λ25s, which indicates the probability of volcanic heart rate deviations of departure from each standard deviation level, as a marker of sympathetic cardiac overdrive. L/T-type calcium channel blocker (L/T-CCB), azelnidipine, decreases sympathetic nerve activity in experimental and clinical studies.

Methods: In 43 hypertensive patients with CKD under treatment with an angiotensin receptor blocker (ARB), we investigated whether 8-week add-on L/T-CCB treatment could restore HRV.

Results: Means of all normal-to-normal intervals over 24 h (p<0.0001) and DC (p=0.002) increased, and λ25s (p=0.001) decreased regardless of gender, age, renal function or blood pressure, while no significant changes were observed in the other HRVs.

Conclusions: Reduction of λ25s is useful to assess the effect of sympathoinhibitory treatment. Further studies are needed to investigate if the restoration of HRV is directly associated with the improvement of prognosis in patients with CKD.

Keywords
Angiotensin receptor blocker, calcium channel blocker, chronic kidney disease, deceleration capacity, non-Gaussian heart rate variability

Date received: 16 January 2016; accepted: 12 March 2016

Introduction
Elevated salt-sensitivity of blood pressure (BP) and inappropriate activation of the renin–angiotensin–aldosterone system and the sympathetic nervous system play important roles in high BP and the high incidence of cardiovascular diseases in patients with chronic kidney disease (CKD).

Our group has reported the associations of BP with salt-sensitivity¹ and the intrarenal renin–angiotensin–aldosterone system,² and it is well known that the sympathetic nervous system can be over-activated in end-stage renal disease³ and even in the early stage of CKD.⁴ In fact, we previously reported abnormal heart rate variability (HRV) in patients undergoing hemodialysis.⁵ The pathologic

¹Department of Cardio-Renal Medicine and Hypertension, Nagoya, Japan
²Department of Mechanical Science and Bioengineering, Osaka University, Osaka, Japan
³Department of Physical and Health Education, University of Tokyo Graduate School of Education, Tokyo, Japan
⁴Department of Medical Education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Corresponding author:
Michio Fukuda, Division of Nephrology and Dialysis Center, Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, 467-8601 Nagoya, Japan.
Email: m-fukuda@med.nagoya-cu.ac.jp
sympathetic activity can alter HRV, and the altered HRV has prognostic importance, so that reducing sympathetic activity may be an important strategy in patients with CKD. The conventional HRV measures from 24-h ambulatory electrocardiogram (ECG) are known to provide the indices of autonomic neural functions, and some of them have also been recognized as mortality predictors by the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Novel nonlinear HRVs, including heart rate turbulence (HRT), deceleration capacity (DC), and fractal scaling exponents also have greater predictive power than conventional HRV measures for mortality after myocardial infarction. Recently, we proposed that the non-Gaussian index of HR (\(r_{30s}\)), which indicates the probabilities of volcanic heart rate deviation from each standard deviation (SD) level, can serve as a marker of sympathetic heart rate and can be used as a predictor of mortality and morbidity in cardiovascular diseases.

Renin–angiotensin system (RAS) inhibitors (i.e. angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs)) are first-line antihypertensive agents for patients with CKD and can assuage sympathetic activity. Most patients with CKD will require two or more antihypertensive agents to achieve the target BP goal, and diuretics and calcium channel blockers (CCBs) are used as second-line antihypertensives. Treatment with diuretics may activate sympathetic activity due to body fluid deprivation, and treatment with amiodipine, L-type dihydropyridine (DHP) CCB, may cause reflex sympathetic stimulation due to excessive and rapid reduction of BP. Meanwhile L/T-type and L/N-type DHP-CCBs, such as benidipine, azelnidipine, cilnidipine and efonidipine, are potent antihypertensives with sympathetic inhibitory effects. For example, L/T-type calcium channel blocker (L/T-CCB) azelnidipine decreases sympathetic activity in experimental models and in clinical study. In patients with hypertension, azelnidipine reduced muscle sympathetic nerve activity and HR while amiodipine increased them. In the present study, we therefore investigated whether add-on administration of L/T-CCB restored HRV, including conventional and novel HRV measures in hypertensive patients with CKD under treatment with ARB.

**Material and methods**

**Subjects**

To be eligible for the study, patients had to fulfill the following criteria: (1) diagnosed with CKD based on Kidney Disease Outcomes Quality Initiative (K/DOQI) criteria of a glomerular filtration rate (GFR) <60 ml/min/1.73 m², or GFR \(\geq\)60 ml/min/1.73 m² with accompanying proteinuria (defined as >300 mg/gCre); (2) treatment with an ARB (olmesartan) for at least 8 weeks prior to enrollment; (3) office BP >130/80 mmHg (or 125/75 mmHg if proteinuria \(\geq\)1 g/day); and (4) no contraindications for treatment with azelnidipine. Patients were excluded if they had (1) received treatment with CCBs in the 8 weeks before enrollment; (2) myocardial infarction, stroke, or a major surgical procedure in the previous 2 months, significant valvular disease or congenital heart disease, atrial fibrillation or flutter, high-grade heart block or permanent pacemaker implantation, chronic obstructive lung disease, severe hepatic disease, malignant neoplasm, or another physical or mental problem that could limit their normal daily activities; or (3) polycystic kidney disease as the original disease underlying CKD, because this condition is often accompanied by sympathetic hyperactivity, regardless of renal function. All subjects were enrolled after providing informed consent to participate in the study. The study protocol was approved by the Ethics Review Committee of Nagoya City University Graduate School of Medical Sciences and the study was conducted in accordance with the Declaration of Helsinki. In total, 45 consecutive patients with CKD (32 men and 13 women; 59±15 years; body mass index (BMI): 23.6±4.6 kg/m²) were eligible for the study, but two showed frequent ventricular ectopic beats >10% of the total recorded beats in their 24-h ECG (data-exclusion criteria for HRV analysis as mentioned below) at baseline under the preceding treatment with ARB. Accordingly, 43 patients with CKD (30 men and 13 women; 57±15 years old; BMI: 23.2±4.1 kg/m²) were studied.

**Study protocol**

At baseline, which was defined as the time when subjects had taken olmesartan (20–40 (23±8) mg/day) for at least 8 weeks, ambulatory 24-h ECG was recorded with a portable recorder (RAC-3103, Nihon Koden, Tokyo, Japan) during usual daily activities. After baseline examinations, subjects received single daily doses of azelnidipine (16 mg/day) in the morning. The BP goal was \(<130/80\) mmHg \(<125/75\) mmHg if daily proteinuria was \(\geq\)1.0g) for patients with BP above these values. During the 8-week study period, changes in the dosage of olmesartan or additional administration of other antihypertensives were not allowed. When office or home systolic BP fell below 100 or 95 mmHg, respectively, or a patient felt postural dizziness, the dose of antihypertensive agent was decreased and the patient was excluded from the study. Ambulatory 24-h ECG was recorded again after the 8-week add-on L/T-CCB treatment to preceding ARB.

**HRV analysis**

Ambulatory ECG signals were digitized at 125 Hz and 12 bits with an ECG scanner (DSC-3300, Nihon Koden, Japan).
We calculated non-Gaussianity index of HRV, $\lambda_{25s}$. The suitable for analysis were obtained in 24-h ECG. Finally, Of note, HRT was measured only when >5 isolated PVCs totally abnormal (category 1), and abnormal (category 2). the HRT patterns are classified as normal (category 0), par-

HRT is defined by negative TO and TS >2.5 ms/beat, and elsewhere.24,25 $\lambda_{25s}$ indicates probabilities of the volcanic ground and a mathematical description have been described intermittency of hydrodynamic turbulence. The back-

derived from a method for analyzing multi-scale statistics (LF/HF).6 We also calculated newly recognized mortality frequency (VLF, 0.003–0.04 Hz) and ultra-low-frequency (0.40 Hz), low-frequency (LF, 0.04–0.15 Hz), very-low-

index (HRVTI), the power of high-frequency (HF, 0.15–

(0.25th order moment ($q=0.25$)) to emphasize the center part of probability density function and to reduce the effects of large outliers caused by ectopic beats. Recently, we have reported that an increase in non-Gaussianity of HRV at time scale of 25 seconds ($\lambda_{25s}$) is associated exclusively with increased cardiac mortality risk independent of clinical risk factors and other HRVs in patients with a history of acute myocardial infarction (AMI).12 We therefore used $\lambda_{25s}$ to characterize the non-Gaussian nature of HRV.

The control data for the HRV analysis were obtained from 43 age-, gender-, and BMI-matched persons, who underwent 24-h ambulatory ECG for the evaluation of chest discomfort under no medication of antihypertensive agents, but were proven not to have any cardiac and kidney diseases nor hypertension ($n=43$). For ethical reasons, ARB and L/T-CCB were not started in these 43 persons.

**BP and albuminuria**

Office BP and HR were determined as averages of two readings in two visits at baseline and in two visits after 8-week add-on L/T-CCB treatment. BP and HR were measured with the validated automated oscillometric sphygmomanometer (MPV3301, Nihon Koden, Tokyo, Japan) after subjects had been seated for at least 5 min. At each visit, spot urine and blood samples were collected to calculate the ratio of urinary albumin to urinary creatinine (mg/gCre) and the estimated GFR (eGFR) using the Japanese equation for eGFR:26

$$eGFR = 194 \times \left[ \frac{\text{serum creatinine concentration, mg/dL}}{1.094} \right]^{-0.287} \times \left[ \frac{\text{age, yrs}}{1.094} \right]^{-0.287} \times [1 \text{ for male; } 0.739 \text{ for female}].$$

**Statistical analysis**

Results are expressed as means $\pm$ SD, or as median (inter-
quartile range, IQR) according to their distribution. Data distributions were tested using the Kolmogorov–Smirnov test, and variables that were not normally distributed were analyzed after log transformation. Differences in parameters between baseline and ARB plus L/T-CCB combination treatment were examined by Student t-test for paired samples or by Wilcoxon signed-rank test, as appropriate.
Correlations among quantitative variables were evaluated by the least-squares method. Relationships between the changes in the variables were analyzed by linear regression through the origin. The effects of baseline characteristics on the changes in HRV measures, significantly altered by add-on L/T-CCB treatment, were examined by repeated measures analysis of variance (ANOVA). The model incorporated baseline demographic variables, including age, sex, and baseline values of eGFR and systolic BP. Forward stepwise multiple regression analysis was conducted to compare the contribution of the change in HRVs, which showed significant correlation with systolic BP at baseline, to the change in systolic BP. Statistical analyses were performed using SPSS Statistics 22 (IBM Corp., NY, USA); \(p<0.05\) was considered to be significant.

**Results**

**Baseline**

At baseline under ARB treatment, the mean±SD or median (IQR) for proteinuria, eGFR, systolic BP, diastolic BP, and HR were 845 (420–2210) mg/gCre (geometric mean±SD, 950±4 mg/gCre), 50±25 ml/min/1.73 m², 139±14 mmHg, 82±11 mmHg, and 77±12 rpm, respectively (Table 1). HRVs at baseline are shown in Table 2. No significant difference was observed between baseline HRVs and their control values. Among HRVs, only DC correlated significantly with eGFR (\(r=0.36, p=0.02\)). Baseline systolic BP correlated directly with \(\lambda_{25s}\) (\(r=0.43, p=0.004\)) and \(\alpha_2\) (\(r=0.47, p=0.001\)), and inversely with DC (\(r=-0.41, p=0.006\)) and LF/HF (\(r=-0.35, p=0.02\)), but did not show significant relationships with other HRVs. Only 10 patients met precondition (>5 isolated PVC) to determine HRT categories (Appendix 1).5,10 Five of these patients had normal HRT (Category 0); one had partially abnormal (category 1); and four patients had abnormal HRT (category 2).

**Effects of add-on azelnidipine**

None of the participants experienced their office or home systolic BP of <100 or 95 mmHg, respectively, or felt postural dizziness to discontinue the study treatment. The addition of L/T-CCB to ARB treatment decreased systolic BP, diastolic BP and proteinuria (Table 1). However, eGFR and HR were not changed significantly by treatment with L/T-CCB.

HRVs during add-on of L/T-CCB to ARB treatment are shown in Table 2. MNN increased significantly (\(p=0.03\)), but no significant difference was observed between other HRVs and the control values. HRT during ARB treatment was analyzable in 10 patients (Appendix 1).7,10 Therefore, our study cannot provide statistical power to examine the change in HRT. Change in systolic BP correlated positively with the change in \(\lambda_{25s}\) (\(r=0.41, p=0.006\)), and inversely with the change in DC (\(r=-0.41, p=0.006\)), but did not correlate with the changes in LF/HF (\(r=-0.23, p=0.1\)) or \(\alpha_2\) (\(r=-0.07, p=0.7\)). The change of DC correlated inversely with that of \(\lambda_{25s}\) (\(r=-0.38, p=0.01\), Figure 2). When analyzed by stepwise multiple regression analysis (\(R^2=0.17, p=0.006\)), the main determinants of change in systolic BP was the change in \(\lambda_{25s}\) (\(\beta=0.67, F=8.5\)), rather than the change in LF/HF, \(\alpha_2\) or DC.

**Table 1. Clinical characteristic of patients and the changes with 8-week add-on treatment with L/T-CCB, azelnidipine.**

|                | ARB               | ARB+L/T-type CCB   | p-value |
|----------------|------------------|-------------------|---------|
| Proteinuria mg/gCre (geometric mean) | 845 (420–2210) | 490 (185–1235)    | 0.0002  |
| Proteinuria mg/gCre (geometric mean) | (950±4)          | (480±4)           | <0.0001 |
| eGFR, ml/min/1.73 m² | 50±25            | 49±25             | 0.09    |
| Systolic BP, mmHg | 139±14           | 121±14            | <0.0001 |
| Diastolic BP, mmHg | 82±11            | 71±8              | <0.0001 |
| Heart rate, rpm   | 77±12            | 73±14             | 0.1     |

Values are expressed as the mean ± SD, or median (IQR) (n=43).
ARB: angiotensin receptor blocker; CCB: calcium channel blocker.

**Effects of baseline clinical characteristics**

Repeated measures ANOVA revealed no significant effects of gender, age, or baseline values of eGFR or systolic BP on the decrease in \(\lambda_{25s}\), or on the increase in MNN and DC with add-on L/T-CCB treatment (Table 3).

**Discussion**

This study is the first study to report the effects of sympatholytic L/T-type CCB, azelnidipine, on conventional and novel HRVs in clinical practice. We observed that add-on administration of L/T-CCB increases MNN and DC, and decreases \(\lambda_{25s}\) in patients with CKD under ARB treatment regardless of their gender, age or baseline eGFR or BP. Clinical studies have reported that beta-blockers were
associated with lower $\lambda_{25s}$, supporting $\lambda_{25s}$ as a marker of sympathetic nerve activity.\textsuperscript{11,12} In fact, our study found that sympatholytic L/T-type CCB attenuated $\lambda_{25s}$. On the other hand, decreases in conventional HRV measures, such as SDNN, HRVTI, ULF, VLF, LF and HF have been thought to reflect cardiac vagal dysfunction.\textsuperscript{6} Nonlinear HRV measures, such as DC, scaling exponent $\alpha_1$, and spectral exponent $\beta$ are related to complex interplays between vagal and sympathetic functions,\textsuperscript{8,9,27,28} and abnormal HRT

### Table 2. Changes in heart rate variabilities with 8-week add-on administration of azelnidipine in hypertensive patients with chronic kidney disease under treatment with olmesartan.

|                        | Control      | ARB          | ARB + L/T- CCB | $p$-value* |
|------------------------|--------------|--------------|----------------|------------|
| **Time domain measures** |              |              |                |            |
| Mean NN interval (ms)  | 817 ± 142    | 835 ± 112    | 872 ± 125\textsuperscript{1} | <0.0001    |
| SDNN (ms)              | 136 ± 47     | 130 ± 38     | 133 ± 37       | 0.3        |
| SDANN (ms)             | 123 ± 44     | 119 ± 37     | 124 ± 37       | 0.2        |
| RMSSD (ms)             | 25 (19–38)   | 25 (16–34)   | 24 (19–31)     | 0.1        |
| **Time domain geometric measures** |            |              |                |            |
| HRVTI (ms)             | 36 ± 13      | 32 ± 10      | 34 ± 10        | 0.2        |
| **Frequency domain measures** |            |              |                |            |
| Total power            | 9.20 ± 0.68  | 9.03 ± 0.69  | 9.09 ± 0.63    | 0.5        |
| ULF [ln(ms$^2$)]       | 8.94 ± 0.70  | 8.79 ± 0.71  | 8.86 ± 0.66    | 0.5        |
| VLF [ln(ms$^2$)]       | 6.96 ± 0.73  | 6.79 ± 0.74  | 6.81 ± 0.77    | 0.8        |
| LF [ln(ms$^2$)]        | 5.91 ± 1.00  | 5.61 ± 1.20  | 5.65 ± 1.14    | 0.7        |
| HF [ln(ms$^2$)]        | 4.99 ± 1.35  | 4.79 ± 1.17  | 4.77 ± 1.06    | 0.9        |
| LF/HF                  | 2.96 (1.63–4.16) | 2.48 (1.53–3.88) | 2.58 (1.64–4.05) | 0.4        |
| Spectral exponent $\beta$ | 1.36 ± 0.15  | 1.35 ± 0.13  | 1.36 ± 0.13    | 0.6        |
| **Nonlinear measures** |              |              |                |            |
| Scaling exponent $\alpha_1$ | 1.19 ± 0.28  | 1.15 ± 0.28  | 1.17 ± 0.23    | 0.5        |
| Scaling exponent $\alpha_2$ | 1.12 ± 0.05  | 1.13 ± 0.06  | 1.13 ± 0.06    | 0.9        |
| DC (ms)                | 6.71 ± 2.32  | 6.17 ± 1.84  | 6.55 ± 1.85    | 0.002      |
| $\lambda_{25s}$        | 0.56 ± 0.17  | 0.56 ± 0.15  | 0.50 ± 0.12    | 0.001      |

Values are expressed as the mean ± SD, or median with interquartile range ($n=43$). ARB: angiotensin receptor blocker; CCB: calcium channel blocker. Abbreviations for HRV measures are explained in the text. *$p$-values were for comparison between ARB and ARB+L/T-CCB; \textsuperscript{1}No significant difference was observed between baseline HRVs and their control values; and MNN during combination therapy with L/T-CCB and ARB was higher than the control value ($p=0.03$), but no significant difference was observed between other HRVs and the control values.

**Figure 1.** Non-Gaussianity index $\lambda_{25s}$ before and during the treatment with ARB+ L/T-type CCB. Add-on treatment with sympatholytic L/T-type CCB, azelnidipine, decreases $\lambda_{25s}$ in patients with CKD under ARB treatment (values are shown in Table 2, $p=0.001$). ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CKD: chronic kidney disease.

**Figure 2.** Relationship between the change in non-Gaussianity index $\lambda_{25s}$ and the change in deceleration capacity (DC). Inverse correlation was found between the changes in $\lambda_{25s}$ and DC.
reflects the impairment of cardiac vagal reflex through the baroreceptor reflex mechanism.7,10

As well as for assessment of cardiac autonomic functions, the analysis of HRV has been developed to predict the risk for mortality and adverse cardiovascular events. A variety of HRV measures have been proposed as predictors of increased risk for sudden cardiac death and all-cause mortality in patients after AMI7–9,12 and in those with heart failure11 and end-stage renal disease.5,28 For example, it was reported that lower values of SDNN, HRVTI, VLF, LF and LF/HF ratio were significant predictors of all-cause mortality in 446 survivors of AMI with a depressed left ventricular function.9 In contrast to these measures, non-Gaussianity index of λ25s is a unique measure of HRV. An increase, but not a decrease, in λ25s is associated with an adverse prognosis in patients with cardiac diseases,11,12 Furthermore, the predictive power of λ25s is independent of those of the other HRV measures.11,12 In the present study, λ25s significantly decreased with L/T-CCB, while most HRV measures (attributable to vagal function) tended to increase but their increase was not significant. This observation is consistent with the fact that azelnidipine assuages sympathetic nerve activity rather than vagal nerve activity.

Use of a short-acting DHP-CCB is associated with increased risk of a cardiovascular event, probably due to reflex activation of sympathetic nerve activity caused by excessive and rapid reduction of BP.29–31 Even among long-acting DHP-CCBs, there is controversy whether amlodipine can stimulate sympathetic nerve activity and increase HR.32–34 In contrast, RAS inhibitors including ARBs are known to reduce sympathetic neural activity,13 which is recognized as an advantage of them over DHP-CCB. Azelnidipine, a highly lipid-soluble L/T-type DHP-CCB, has been reported to reduce sympathetic nerve activity.15,17–19,35 Direct measurement of sympathetic nerve activity during treatment with azelnidipine has also been studied in experimental model. Shokoji et al.17 implanted a renal nerve electrode in spontaneously hypertensive rats, and found that the sympathoinhibitory effects of azelnidipine were associated with baroreflex inhibition. Konno and colleagues18 reported that azelnidipine could reduce oxidative stress in the rostral ventrolateral medulla (RVLM; the vasomotor center determining sympathetic outflow) through the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and upregulation of Cu/Zn- and Mn-superoxide dismutase (SOD). Treatment with azelnidipine also increased endothelial nitric oxide expression levels in the brain, heart and aorta.35 In a recent study of hypertensive patients, azelnidipine reduced muscle sympathetic nerve activity while amlodipine increased it.19 Furthermore, combined treatment with an ARB and azelnidipine has been reported to confer greater benefits for prevention of cardiovascular events in patients with CKD than treatment with high-dose olmesartan alone.36 We therefore hypothesized that the combined use of azelnidipine further attenuates sympathetic nerve activity even in patients under ARB treatment. This hypothesis is supported by the reduction of λ25s in our study. Prospective studies are desirable to confirm the direct associations between the reduction in λ25s, with sympatholytic agents and prognostic improvement in patients with CKD.

As mentioned above, HF, RMSSD and DC have been lumped together as a marker of vagal nerve activity. In the present study, however, the increase in DC with add-on treatment with L/T-CCB was accompanied by no significant changes in HF or RMSSD. Change in systolic BP correlated inversely with the change in DC, but did not correlate with the changes in HF or RMSSD. In a previous cohort study of 281 patients with end-stage renal disease (median follow-up, 87 months), we also observed that a decrease in DC predicts increased risk for all-cause mortality, while HF and RMSSD did not.28 In addition, we previously observed that DC correlated inversely with λ25s,12 and in the present study the change of DC correlated inversely with that of λ25s. On the basis of these findings, we speculate that DC is not a simple measure of vagal function but a product of complex interplay between sympathetic and vagal nerve activities.

The limitations of the study include the small number of subjects, and the lack of a placebo-treated group. No significant difference was observed between HRVs during ARB treatment and their control values. RAS inhibitors have been known to reduce sympathetic neural activity,13 but we could not determine whether preceding treatment with ARB had lowered λ25s before the initiation of azelnidipine.

---

Table 3. Repeated measures ANOVA of the effects of baseline clinical characteristics on the changes in MNN, DC, and λ25s.

| Factors          | Significance of effect (p values) |
|------------------|----------------------------------|
|                  | Increase in MNN | Increase in DC | Decrease in λ25s |
| Gender           | 0.9              | 0.9            | 0.3             |
| Age              | 0.4              | 0.8            | 0.4             |
| Baseline eGFR    | 0.6              | 0.8            | 0.4             |
| Baseline SBP     | 0.7              | 0.9            | 0.3             |

Data are p-values for the effect of factors in repeated measures ANOVA models including gender, age, baseline eGFR, and baseline SBP as explaining factors on the changes in MNN, λ25s, or DC during add-on treatment with L/T-CCB, azelnidipine.
Although experimental studies have suggested that azelnidipine decreases sympathetic nerve activity via an antioxidant effect in the RVLM,\(^8\) we could not clarify the mechanisms of the reduction in \(\lambda_{25s}\), with azelnidipine.

**Conclusion**

In conclusion, 8-week add-on administration of L/T-type CCB, azelnidipine, increases MNN and DC, and reduces \(\lambda_{25s}\) during daily activities in hypertensive CKD patients under treatment with ARB. The pathologic sympathetic activity can alter HRV, and the altered HRV has prognostic importance, so that reducing sympathetic activity would be an important strategy in patients with CKD. The reduction of \(\lambda_{25s}\) is useful to assess the effect of sympathoinhibitory agents. Further studies are needed to investigate if the increases in MNN and DC, and the reduction in \(\lambda_{25s}\) with medical treatment, are directly associated with the improvement of prognosis in these patients.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Supplemental material**

The online figures are available at http://jra.sagepub.com/supplemental

**References**

1. Kimura G, Saito F, Kojima S, et al. Renal function curve in patients with secondary forms of hypertension. *Hypertension* 1987; 10: 11–15.
2. Fukuda M, Urushihara M, Wakamatsu T, et al. Proximal tubular angiotensinogen in renal biopsy suggests nondipper BP rhythm accompanied by enhanced tubular sodium resorption. *J Hypertens* 2012; 30: 1453–1459.
3. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med* 1992; 327: 1912–1918.
4. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. *Hypertension* 2011; 57: 846–851.
5. Fukuta H, Hayano J, Ishihara S, et al. Prognostic value of nonlinear heart rate dynamics in hemodialysis patients with coronary artery disease. *Kidney Int* 2003; 64: 641–648.
6. Camm AJ, Malik M, Bigger JT Jr, et al; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. *Circulation* 1996; 93: 1043–1065.
7. Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. *Lancet* 1999; 353: 1390–1396.
8. Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: Cohort study. *Lancet* 2006; 367: 1674–1681.
9. Huikuri HV, Mäkikallio TH, Peng CK, et al. Fractal correlation properties of R–R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. *Circulation* 2000; 101: 47–53.
10. Barthel P, Schneider R, Bauer A, et al. Risk stratification after acute myocardial infarction by heart rate turbulence. *Circulation* 2003; 108: 1221–1226.
11. Kiyono K, Hayano J, Watanabe E, et al. Non-Gaussian heart rate as an independent predictor of mortality in patients with chronic heart failure. *Heart Rhythm* 2008; 5: 261–268.
12. Hayano J, Kiyono K, Struzik ZR, et al. Increased non-Gaussianity of heart rate variability predicts cardiac mortality after an acute myocardial infarction. *Front Physiol* 2011; 2: 65.
13. Klein IH, Litgenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. *J Am Soc Nephrol* 2003; 14: 425–430.
14. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311: 507–520.
15. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure. *Hypertens Res* 2003; 26: 201–208.
16. Hoshide S, Kario K, Mitsushashi T, et al. Is there any difference between intermediate-acting and long-acting calcium antagonists in diurnal blood pressure and autonomic nervous activity in hypertensive coronary artery disease patients? *Hypertens Res* 2000; 23: 7–14.
17. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. *Hypertens Res* 2005; 28: 1017–1023.
18. Konno S, Hirooka Y, Araki S, et al. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. *J Cardiovasc Pharmacol* 2008; 52: 555–560.
19. Inomata J, Murai H, Kaneko S, et al. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. *J Hypertens* 2014; 32: 1898–1904.
20. Sakata K, Shirotani M, Yoshida H, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. *Hypertension* 1999; 33: 1447–1452.
21. Harada K, Nomura M, Nishikado A, et al. Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. *Circ J* 2003; 67: 139–145.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classifi-
23. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. *J Am Soc Nephrol* 2001; 12: 2427–2433.

24. Kiyono K, Struzik ZR, Aoyagi N, et al. Critical scale invariance in a healthy human heart rate. *Phys Rev Lett* 2004; 93: 178103.

25. Kiyono K, Struzik ZR and Yamamoto Y. Estimator of a non-Gaussian parameter in multiplicative log-normal models. *Phys Rev E Stat Nonlin Soft Matter Phys* 2007; 76: 041113.

26. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009; 53: 982–992.

27. Huikuri HV, Perkiömäki JS, Maestri R, et al. Clinical impact of evaluation of cardiovascular control by novel methods of heart rate dynamics. *Philos Transact A Math Phys Eng Sci* 2009; 367: 1223–1238.

28. Suzuki M, Hiroshi T, Aoyama T, et al. Nonlinear measures of heart rate variability and mortality risk in hemodialysis patients. *Clin J Am Soc Nephrol* 2012; 7: 1454–1460.

29. Alderman MH, Cohen H, Roqué R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. *Lancet* 1997; 349: 594–598.

30. Furberg CD, Psaty BM and Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. *Circulation* 1995; 92: 1326–1331.

31. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. *JAMA* 1995; 274: 620–625.

32. Eguchi K, Kario K and Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. *Hypertens Res* 2002; 25: 329–333.

33. Grassi G, Spaziani D, Seravalle G, et al. Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. *Hypertension* 1999; 33: 671–675.

34. Hamada T, Watanabe M, Kaneda T, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. *J Hypertens* 1998; 16: 111–118.

35. Kimura Y, Hirooka Y, Sagara Y, et al. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. *Clin Exp Hypertens* 2007; 29: 13–21.

36. Kim-Mitsuyama S, Ogawa H, Matsu K, et al. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. *Kidney Int* 2013; 83: 167–176.
Appendix 1. Heart rate turbulence

HRT describes fluctuations of the sinus rhythm cycle length after PVCs. The early acceleration and late deceleration of sinus rate after PVC are quantified by two parameters: the TO and TS. Turbulence onset was calculated as follows:

$$\text{TO} = \frac{\left(\text{RR}_2 + \text{RR}_1\right) - \left(\text{RR}_2 + \text{RR}_1\right)}{\left(\text{RR}_2 + \text{RR}_1\right)} \times 100 \%$$

where RR_2 and RR_1 are the two R–R intervals immediately preceding PVC coupling interval, and RR_3 and RR_4 are the two R–R intervals immediately following the compensatory pause. TS is defined as the maximum positive regression slope assessed over any five consecutive sinus rhythm R–R intervals within the first 15 sinus rhythm R–R intervals after the PVC. In normal subjects, the initial brief acceleration of sinus rate after the PVC is characterized by a negative TO, and the subsequent rate deceleration is characterized by a positive TS. Thereafter, the response patterns are classified as normal (category 0), partially abnormal (category 1), and abnormal (category 2). HRT is measurable only when >5 isolated PVCs suitable for analysis are obtained in 24-h electrocardiography.

Appendix 2. Non-Gaussianity index $\lambda$

Following four steps show the estimation procedure of the non-Gaussianity index of HRV at time scale “s” ($\lambda_s$). In step 1, time series of NN R–R intervals are resampled at equally spaced time intervals with $\Delta t=250$ms (4 Hz) using cubic spline interpolation, yielding interpolated time series $\{b(t)\}$. After subtracting average interval $b_{\text{ave}}$, integrated time series $\{B(t)\}$ are obtained by integrating $\{b(t)\}$ over the entire length.

$$B(t) = \sum_{i=1}^{t/\Delta t} \{b(i\Delta t) - b_{\text{ave}}\}$$

In step 2, the local trend of $\{B(t)\}$ is eliminated by third-order polynomial that is fit to $\{B(t)\}$ within moving windows of length $2s$, where $s$ is the scale of analysis. In step 3, intermittent deviation $\Delta s B(t)$ is measured as the increment with a time lag “s” of the detrended time series $\{B'(t)\}$. For instance, in a window from T−s to T+s, the increments are calculated as

$$\Delta s B(t) = \left\{B(t + s/2) - f_{\text{fit}}(t + s/2)\right\} - \left\{B(t - s/2) - f_{\text{fit}}(t - s/2)\right\}$$

where $T-s/2 \leq t < T+s/2$ and $f_{\text{fit}}(t)$ is the polynomial representing the local trend of $\{B(t)\}$, of which the elimination assures the zero-mean probability density function in the next step. In step 4, $\{\Delta s B\}$ are standardized to have zero mean and unit variance. Then, the non-Gaussianity index $\lambda_s$ is estimated as

$$\lambda_s = \sqrt{\frac{2}{q(q-2)}} \left[\ln \left(\frac{\sqrt{\pi} \langle |\Delta s B|^q \rangle}{2^{q/2}}\right) - \ln \Gamma \left(\frac{q+1}{2}\right)\right]$$

where $\langle |\Delta s B|^q \rangle$ denotes an estimated value of the $q$-th order absolute moment of $\{\Delta s B\}$. In our analysis, the parameters in the above equation are set as $s = 25$ s and $q = 0.25$. The estimated value of $\lambda_s$ can be used to characterize deviation from Gaussianity (normality of the observed distribution). If the $\lambda_s$ is close to zero, the observed probability distribution of $\{\Delta s B\}$ is close to a Gaussian distribution. On the other hand, a larger value of $\lambda_s$ means that the observed distribution has fatter tails and a sharper peak in comparison with the Gaussian distribution (supplementary Figure 1).